Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis
Pathogenicity of Species of the Achromobacter Genus in Patients With Cystic Fibrosis: a Prospective Multicentre Exploratory Study of a Cohort in Réunion Island.
Centre Hospitalier Universitaire de la Réunion
35 participants
Mar 12, 2024
OBSERVATIONAL
Conditions
Summary
The pathogenicity of Achromobacter bacteria is not yet well established, but studies show a decline in respiratory function and an increase in mortality associated with chronic colonisation, making it possible to classify the Achromobacter genus as an emerging pathogen in cystic fibrosis. It is possible that certain species or clones are more virulent or resistant, requiring the adaptation of measures to prevent cross-transmission in the centres concerned. However, until now, the identification of Achromobacter species has involved the use of molecular biology techniques that are not routinely applicable in diagnostic laboratories, limiting studies and the collection of epidemiological data. Recently, a database using MALDI-TOF mass spectrometry has been built for rapid and accurate species identification. In view of the local epidemiology and the current lack of data, it would be necessary and interesting to use this tool to study a cohort of cystic fibrosis patients in Réunion island (North and South sites) to see whether one species has a greater clinical impact than another (pathogenicity), and/or is more responsible for chronic colonisation.
Eligibility
Inclusion Criteria4
- Minor or major cystic fibrosis patients
- Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period.
- Patients living in La Réunion island.
- Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself)
Exclusion Criteria2
- Patients without cystic fibrosis.
- Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion. The micro-organisms will be quantified. The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021).
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06371261